UFP Technologies (UFPT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual Meeting scheduled for June 4, 2026, will be held virtually with voting on director elections, executive compensation, and auditor ratification.
Seven directors are nominated for election to serve until the 2027 Annual Meeting.
CEO transition planned: R. Jeffrey Bailly to retire as CEO and become Executive Chairman; Mitchell C. Rock to become CEO effective June 4, 2026.
Proxy materials, annual report, and voting instructions are available online.
Voting matters and shareholder proposals
Proposals include election of seven directors, advisory vote on executive compensation, and ratification of Grant Thornton LLP as independent auditor.
Board recommends voting FOR all nominees and proposals.
Shareholders may submit proposals for the 2027 meeting by specified deadlines and procedures.
Board of directors and corporate governance
85.7% of director nominees are independent; all board committees are fully independent.
Board diversity includes 29% women; Lead Independent Director presides over executive sessions.
Board structure separates Executive Chairman and CEO roles; Lead Independent Director ensures balance.
Annual election of all directors; no shareholder rights plan in place.
Board and committee charters, governance guidelines, and codes of ethics are reviewed annually.
Latest events from UFP Technologies
- Targeting 12–18% growth, the company invests in medtech innovation and global expansion.UFPT
16th Annual East Coast IDEAS Conference11 Jun 2026 - Global MedTech manufacturer targets 12-18% annual growth with proven scale and innovation.UFPT
Investor presentation10 Jun 2026 - All proposals, including director elections and auditor ratification, were approved.UFPT
AGM 20267 Jun 2026 - Q1 2026 revenue up 4.1% to $154.2M, with MedTech growth and margin gains amid ongoing risks.UFPT
Q1 20268 May 2026 - Net income up 15.8% and sales up 19.5% to $602.8M, driven by medical market growth.UFPT
Q4 20257 Apr 2026 - Exclusive materials, strategic acquisitions, and strong contracts fuel high-margin growth.UFPT
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - MedTech-focused manufacturer targets 12–18% revenue growth and 17–20% margins via innovation and acquisitions.UFPT
Investor presentation3 Mar 2026 - Exclusive materials, strategic acquisitions, and medtech focus drive robust growth and margins.UFPT
15th Annual Midwest IDEAS Investor Conference23 Jan 2026 - Executing on acquisitions and expanding in med tech, with strong customer partnerships and margin gains.UFPT
CJS Securities Annual New Ideas For the New Year Conference 202410 Jan 2026